David A. Dodd Awarded 2005 Oglethorpe Sword By British American Business Group of Atlanta.

ATLANTA -- Serologicals Corporation (NASDAQ: SERO) announced today that David A. Dodd, President and Chief Executive Officer, has recently been awarded the prestigious Oglethorpe Sword, a ceremonial broad sword given annually to an American or British businessperson who has contributed significantly to Anglo-Georgia business interests. The award was presented by Michael Bates, British Consul General of Atlanta, during the annual Oglethorpe Ball, hosted by the British American Business Group of Atlanta (BABG).

Since becoming CEO in 2000, Dodd has raised the profile of Serologicals' presence in the U.K. by expanding the company's operation in Livingston, Scotland, as well as with the acquisitions of Chemicon International, Inc., which bases its European operations in Hampshire, England, and Upstate Group, which has its European headquarters in Dundee, Scotland. Serologicals recently announced its expanded research and development operations at the Dundee facility earlier this month. In conjunction with that event, Mr. Dodd is scheduled to speak at the Bio-Dundee Annual International Conference on Friday, March 18, 2005. More than 200 delegates from the international biotech industry will be in attendance for Dodd's presentation on "Creating a Sustainable Bio-Business."

Dodd is also the outgoing Chairman of the Georgia Biomedical Partnership, which recently awarded him the 2005 Biomedical Industry Growth Award for his work in leading the growth of the life sciences industry in Georgia.

The Oglethorpe Sword is awarded annually by the BABG, and is presented to coincide with the group's annual Oglethorpe Ball. Other recipients have included Pete Correll, CEO of Georgia-Pacific Corporation, and Bill Bullock, former president of Lockheed Martin Corporation.

Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA, is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world's leading provider of monoclonal antibodies for the blood typing industry.

Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA and Celliance Corporation, headquartered in Atlanta, GA.

For more information, please visit our website: www.serologicals.com.